Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yea, we will get there.
I said it and I said it again 2015 is going to be a great year for the company.
It’s started with the Completes Purchase of cGMP-compliant Pilot Production Facility:
NanoViricides now intends to move its operations to the new facility in a phased manner in order to minimize any potential impact on ongoing projects. The Company expects to manufacture its drug candidates for human clinical trials at the new facility.
The Company further reports that all of its drug development programs are progressing satisfactorily.
About the Facility:
The 18,000 sqft building at 1 Controls Drive, Shelton, CT, was completely renovated in order to build a modern, state-of-the-art c-GMP-compliant manufacturing facility for the production of clinical scale quantities of a wide variety of injectable nanomedicines drug substances and drug products, modern nanomedicines research and development facilities, as well as an on-site state-of-the-art nanomedicines analysis and characterization facility. The new facility comprises a small office space, R&D Chemistry Labs, R&D Biology Labs, R&D Analytical Lab and cGMP supporting Analytical Lab, cGMP-compliant raw materials handling and dispensing area, and c-GMP compliant Clean Room Suites for nanomedicines production and product packaging processes. All of the R&D labs employ class 100,000 or cleaner air systems. The clean room suites comprise class 10,000 air quality areas as well as class 1,000 and the ultra-clean class 100 air quality areas (the class specifies the number of particles per 1,000 liters of air). This allows production and handling of nanomedicines with minimal risk of entraining foreign particles. All of the R&D labs employ deionized water. For critical processes, WFI-quality water is also produced on site in quantities needed to support the production scale (WFI = water for injection, comprises a specification of water quality that specifies minimal endotoxins and maximum sterility).
Remember:
The Company reports that all of its drug development programs are progressing satisfactorily and that it will continue to provide updates as appropriate.
in particular, the synthesis of anti-Ebola drug candidates is progressing satisfactorily. The Company has recently reported that it has signed a “Cooperative Research and Development Agreement - Materials Transfer Agreement (CRADA-MTA)” with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) for biological testing of these candidates. The Company is working expeditiously on its anti-Ebola program at present, in order to develop an effective drug candidate that may be available in response to the current Ebola epidemic crisis.
The Company has the ability to produce sufficient quantities of a successful drug candidate for potential field use.
And:
its “Injectable FluCide™” drug candidate for severe influenza has been chosen as one of the “Top Ten Infectious Diseases Projects to Watch” by a panel of industry experts assembled by Informa and the publishers of In Vivo, Startup and The Pink Sheet.
Also for some people who are criticizing the company saying that the tox didn’t start without doing their own due diligence:
Initial large animal safety/toxicology studies in the Company’s FluCide™ drug development program have begun at BASi as previously reported.
In addition, the Company is performing process development and scale up studies on its FluCide™ drug candidate in its existing facilities. The extremely high safety of FluCide has resulted in a very large quantity requirement for the GLP Safety/Toxicology studies, necessitating scale-up studies at this early stage.
And:
The Company estimates that it now has approximately $42.6 Million (M) of current assets plus restricted cash in hand. The Company estimates that this funding is sufficient to enable us to perform initial human clinical trials of our injectable FluCide™ drug candidate, as well as possibly to advance our DengueCide™ orphan drug candidate towards initial human clinical trials. As previously reported, our strong cash position has enabled us to restart our anti-Ebola drug development program in response to the current epidemic. The Company’s estimates are based on its current rate of expenditure and also on certain approximate estimates for clinical development of its drug candidate as gleaned from discussions with various contract research organizations.
So I am not worried about the constant negative and laughable posts against the company.
Prepare to open a bottle of champagne.
This is happening
Salute
FN
And we should have the results very soon.
I can't reply in PM, I am not a pay member.
I don't think he get it.
Pump Terminator Pompa Pompa!
LOL
Thanks anhba for reminding all of us what is happening inside the company! Big news are coming!
Stay tuned!
FN
NNVC is in a great position to succeed. It's a question of weeks!
Stay tuned!
FN
26 children have died from flu as outbreak widens
Liz Szabo, USA TODAY 1:53 p.m. EST January 9, 2015
http://www.usatoday.com/story/news/nation/2015/01/09/flu-deaths-increase/21498903/
Flu is now widespread in 46 states and has killed 26 children, health officials said today.
"This year is shaping up to be a bad one, particularly for people 65 and older," says Thomas Frieden, director of the Centers for Disease Control and Prevention. Children younger than 5 are also at high risk of hospitalization, particularly babies under 6 months, who are too young to be vaccinated.
Flu is hitting the USA especially hard this year for two reasons.
First, the dominant flu strain in circulation is H3N2, a type that tends to cause twice as many hospitalizations and deaths as other strains of flu, Frieden says. Hospitalization rates have risen to 92 per 100,000 people, compared with 52 hospitalizations per 100,000 in a typical year.
"H3N2 is a nastier flu virus than other flu viruses," Frieden says. "Hospitalization rates in the over-65 age group are rising."
Second, the H3N2 viruses used to make this year's influenza vaccines aren't a good match to those spreading throughout the country, the CDC says. That's because about two-thirds of the H3N2 viruses in circulation have mutated significantly since vaccine production began last spring. Drugmakers tend to start making flu vaccines in the spring, in order to produce enough for the fall flu season.
"Even in a good year, the flu vaccine is not as effective as our other vaccines," Frieden says, noting that flu efficacy rates are about 60% to 65%.
Frieden says there are several ways for people to protect themselves.
Flu vaccines. While the flu shot this year may be less effective than usual, Frieden says it's not too late to get a shot. About one-third of the H3N2 viruses in circulation are a good match for those in the vaccine. And vaccines protect against three or four strains of flu. So flu shots may still protect people from other types of flu, such as strains of influenza B, which often show up later in the flu season.
The CDC recommends flu shots for everyone over the age of 6 months.
Only about half of Americans get flu vaccines, the CDC says. Doctors recommend that pregnant women get vaccinated, to provide immunity to babies in the first few months of life.
Antiviral drugs. Frieden also urged patients and doctors to make more use of antiviral drugs, such as Tamiflu and Relenza, which can reduce the risk of complications, hospitalizations and death. While the drugs are most effective if given in the first 24 hours after symptoms appear, Frieden says they may still offer some benefit after that point, especially for elderly people and others at high risk of complications.
Surveys show most Americans don't know there are prescription medicines to treat the flu, Frieden says.
"They work, but they aren't being used nearly enough," Frieden says. A study found that "fewer than one out of five high-risk outpatients who clearly should have gotten treated with antivirals, actually did."
Frieden encouraged doctors to prescribe antivirals immediately when patients have symptoms of the flu — such as fever, headache and body ache — rather than wait for definitive results from tests, which may unnecessarily delay treatment.
Some pharmacies are running short of the drugs, although manufacturers say the overall supply of antivirals is good, Frieden says.
"You may have to call around" to more than one pharmacy, Frieden says.
Pneumococcal shots. This fall, the CDC began encouraging people over age 65 to get two different vaccines against pneumococcus, a bacteria that causes pneumonia. The flu increases the risk of pneumonia, especially in the elderly.
The flu sickens millions of Americans every year, says the CDC's Joseph Bresee, which leads to hundreds of thousands of hospitalizations. Deaths from the flu can range from 5,000 to 50,000 every year, says the CDC.
The USA is about halfway through the flu season now.
Good hygiene. People should wash their hands frequently and cover their coughs, Frieden says. People who are sick should stay home and not go to work or school.
I so agree with L-VUS
It's really disgusting.
If Boniuk is buying,
It's a great sign.
Why did they go for Ebola?
They would never take a risk putting
aside FluCide if they knew that EbolaCide would be tuff to pass.
We don't know what's going on behind the curtains.
I believe that they really found the way to kill any viruses.
Time will tell.
FN
I've got news for you: it's takes time for an unknown biotech company to
go through the process of having a drug approved .
10 years is normal.
bloomvest,
When you will buy a Cide medication in a pharmacie for you or your family,
will sou still say that the company is a scam?
LOL
You are right drkaz, and also today's volume is low. As we can see the trend is not reversing
Some people are looking to lock in a quick profit.
We will see big moves after the result of EbolaCide and FluCide.
FN
The net gain (long-term) for NNVC in value may be significant,.... once that big piece of illiquid infrastructure starts producing a product that can generate revenue. But for the moment - what the market is seeing is the at-hand cash for a company with no existing revenue stream (other than share sales) just went down by a bit more than 10%. This purchase raises the perceived risk (in the short to medium term) that the company will need to do a dilutive share sale sooner than the market might have predicted, and shareprices fell accordingly.
BUT - All of this could change almost instantly once that plant is a net revenue generator to offset that capital input.
"Mr. Market" tends to see only what is immediately estimable and in front of it though,.... When NNVC gets its "breakthough",.... then "Mr. Market" will almost immediately cease to be oblivious.
This hurt the stock much more badly than with a normal financing deal.
Moreover, it is completely unethical for Diwan to sell his shares at this stage of the company development before the company has yielded anything of value to the shareholders and society at large. Diwan is not entitled (from an ethical point of view) to sell his shares as long as NNVC has not yet proved it is a viable and profitable company; which is far from being achieved!
The tox studies won't be completed before many years
And now, even after a Great PR, I read the first comments from the negative.
It make me smile.
I know when the next PR will give another success from the company on Ebola or the flu,
there will always be bad comments about the company and its leaders.
I will not be surprised that when NNVC will have 5 drugs on the market, those same people will still complain and whine.
And it will sell better than Tamiflu.
Just having fun with you.
For my $100,000
By the way, who is your broker?
So you own stocks in a company that you don't like?
You want to be right for your own interest. I think that you will be very disappointed if NNVC succeed this year . It will go against all your criticisms of the last 2 years.
Oh well
You are so good in criticism.
I hope that you are making things happen for yourself r
Drkaz
You make that board interesting.
Shelton drug-development lab targets Ebola cure
http://www.washingtontimes.com/news/2015/jan/3/shelton-drug-development-lab-targets-ebola-cure/
By ED STANNARD - Associated Press - Saturday, January 3, 2015
SHELTON, Conn. (AP) - A company that is developing new anti-viral drugs hopes it will have a cure for Ebola, which is still in the research phase, put on the fast track for development in the fight against the disease.
NanoViricides, whose headquarters are in West Haven, opened its research and development lab in July. The company, with a net worth of $250 million, employs more than 20 and expects to double that in the next two years
U.S. Sen. Richard Blumenthal, D-Conn., recently toured the newly renovated plant. He’s helping the company have its research evaluated by the U.S. Army Medical Research Institute of Infectious Diseases and, once a drug is developed, to move into clinical trials on an emergency basis.
AMRIID evaluates “different approaches to cures for various kind of diseases and they focus very intently on Ebola,” Blumenthal said. “We have expedited their attention on the work being done here.”
The company is operating without government financing now, but, Meeta Vyas, chief financial officer, said if the Ebola drug were successful, “we would apply for a Department of Defense grant.”
NanoViricides is developing potential cures for the flu and HIV as well as Ebola. The flu drug is 18 months from clinical trials, said Anil Diwan, president and chairman, but if an Ebola drug looks promising it would go into trials more quickly because of the emergency in west Africa.
“Once the data from AMRIID comes out, we’ll discuss it with them and then we’ll decide the next step,” Diwan said. “It could be as early as March 15.”
The Shelton lab will enable NanoViricides to ramp up its research and to manufacture the drug if it’s found to succeed against Ebola.
According to the Centers for Disease Control and Prevention, there have been 19,340 cases in Guinea, Sierra Leone and Liberia as of Dec. 20, plus seven in Mali, a new site for the disease. There have been 7,524 confirmed deaths in those four countries, the CDC reported.
Protein Sciences of Meriden, among other companies, is working on an Ebola vaccine. Diwan said NanoViricides, which he launched in 1992, is researching “a completely novel new mechanism. We are defining a new class of drugs.”
If it works, it can be taken not only by people with Ebola but also by others, such as healthcare workers, to prevent contracting the disease.
Diwan described the drug’s action: “We try to replicate how the virus binds to the cell,” so that the ebolavirus is tricked into binding onto the drug instead of the living cell.
“In competition against the cell surface, our stuff wins,” Diwan said.
Read more: http://www.washingtontimes.com/news/2015/jan/3/shelton-drug-development-lab-targets-ebola-cure/#ixzz3NsOp4iQW
Follow us: @washtimes on Twitter
Ebola crisis: Experts warn against complacency in fight to contain worst outbreak in history
By Africa correspondent Martin Cuddihy
Posted yesterday at 8:25pmSat 3 Jan 2015, 8:25pm
PHOTO: The first victim of the Ebola outbreak which has claimed over 7,800 lives is believed to be a two-year-old boy who caught the virus in Guinea. (AFP: Francisco Leong)
RELATED STORY: Scottish medical worker diagnosed with EbolaRELATED STORY: US lab worker possibly exposed to Ebola shows no signs so far
MAP: Guinea
It has been one of the biggest stories of 2014 and it does not look like it is going anywhere.
The Ebola crisis in West Africa has killed thousands of people and it will continue to do so in 2015.
Given the Ebola story has been a constant on the news for the best part of a year, some of the interest has gone. But ignoring the disease is fraught with danger.
On a US talk show recently, White House Ebola response coordinator Ron Klain warned the world against complacency.
"I think we're nearing a pivot point in this, where the number of new cases overall in West Africa has somewhat stabilized," he said.
"But this won't be done until we get all the way to zero. It's like a forest fire: a few embers burning, and the thing can reignite at any time."
A stark warning for an indiscriminate killer.
Scientists now believe the first Ebola victim was a two-year-old boy who caught the disease after playing either in or near a tree that housed a colony of bats.
From there he passed the virus onto his family and then to health workers in Guinea.
They then passed it onto their own families and thus the cycle began.
Ebola spread rapidly from country to country
What helped this become the worst ever outbreak of the disease was the fact the haemorrhagic virus was not identified as Ebola until late in March.
This gave it time to get embedded in the population - dense, hygiene poor rural parts of both Guinea and Liberia. From there it spread to Sierra Leone.
Ebola virus explained
What is Ebola, and how does this highly contagious and deadly disease spread?
Initially the global response was subdued. Ebola was not a new story.
After all, there have been a few major international stories this year: Syria, Ukraine, and various disasters involving planes.
The deputy director of the US Centers for Disease Control in Kenya, Dr Joel Montgomery, has been to West Africa a few times this year.
Dr Montgomery helped to establish new offices in the three hardest hit countries.
When the outbreak was at its worst, in late August and early September, he was there.
"When I arrived it was just a complete and utter disaster. It was very much like a nightmare," he said.
"Seeing people actually die in the streets from Ebola. It was actually very devastating and very difficult to witness."
He paints a grim picture and has repeated the warning of Mr Klain about not becoming complacent.
Most experts believe it will be months, at the very least, before transmissions drop to such a point that the worry can dissipate.
Dr Gavin Macgregor-Skinner, an expert in public health and emergency medicine who has also spent time in West Africa this year, says the global response has failed the region.
"We're not dealing with this as an ongoing public health emergency. And that's been a huge failure."
Cultural practices and superstition key to Ebola spread: medic
It is a multifaceted problem. Compounding issues of poor infrastructure and the slow response by the international community are local superstitions, traditions and a lack of access to basic health services.
A lot of communities hold superstitions in regard to the Ebola detection teams.
People do not realise that soap and water are the best defence, and they sometimes seek help from religion and traditional healers before seeing a doctor.
Media player: "Space" to play, "M" to mute, "left" and "right" to seek.
VIDEO: Dr Joel Montgomery has described the Ebola zone as a "nightmare". (ABC News)
Liberia's chief medical officer Dr Bernice T. Dahn said cultural practises would have to change to beat the virus.
"For the cultural practices, it's not a matter of banning it, it's a matter of behaviour change, behaviour change communication," Dr Dahn said.
"If you ban it, it could go underground and it could make things worse. So it's a matter of educating people, people understanding why things should be done right and not be done the wrong way, and they'll change behaviour."
Changing these cultural practices will take time and that means the disease keeps re-emerging in areas that have been declared Ebola free.
"We're seeing the virus circulate between the three countries. So where one area had beaten Ebola they're now getting new cases in," said Dr McGregor-Skinner.
"Until we change our intervention, until we change our strategy, until we use all the tools in the toolbox, we are going to keep seeing ... this Ebola virus circle amongst the three countries and we're going to keep seeing cases pop up."
Until that stops, the Ebola crisis will continue and you might be reading an iteration of this article this time next year.
More on this story:
The big volume will come with the next PR
To all of us!
Yes Weedie
2015 is the year!
To 2015
And more pictures.
Soon we will have more news.
Until then Enjoy your evening.
FN
Shelton firm on the frontlines of Ebola research
By Brad Durrell on December 31, 2014
http://sheltonherald.com/56772/shelton-firm-is-on-frontlines-of-ebola-researchebola/
A bioscience firm with a large Shelton lab facility is working to create a treatment for Ebola.
Anil R. Diwan, president and chairman of NanoViricides Inc., said his company is focusing on a “highly targeted” approach that would prevent the Ebola virus from multiplying within a person or re-infecting a person.
“We are attacking the virus directly,” he said.
A look inside a restricted lab area in the NanoViricides Inc. facility in Shelton.
Diwan said nanoviricides are particularly effective because they “bind” only to infected cells and likely will work despite any mutations or other changes in the virus.
Nanoviricides are antiviral agents that get virus cells to attach to them so they can surround and trap the virus cells.
U.S. Sen. Richard Blumenthal recently toured the NanoViricides complex on Controls Drive to learn more about the company’s research.
“I’m very impressed by the potential of cutting-edge technology that can save lives,” Blumenthal said.
Expediting the process
Blumenthal’s office recently assisted NanoViricides by getting the U.S. Army Medical Research Institute of Infectious Diseases to look at the company’s research.
“Your staff expedited the process,” said Meeta R. Vyas, NanoViricides chief financial officer. “It was stuck in the bureaucracy.”
U.S. Sen. Richard Blumenthal, left, with Anil R. Diwan, president and chairman of NanoViricides Inc.
After the tour, Blumenthal stressed he isn’t a scientist and doesn’t know what research will be successful, but said NanoViricides’ work “deserves to be evaluated and considered by the Pentagon” due to the urgent need to combat Ebola.
He said Ebola “could be a national security issue,” and finding a cure for the disease has proved elusive so far.
To date, Ebola has infected 19,000 people, mostly in three West African countries. More than two-thirds of people who get Ebola usually die, according to NanoViricides material.
The Army research agency funds research and trials by companies but to date has not provided any money to NanoViricides.
The company hopes to get funding from the Army to begin drug trials for its possible Ebola treatment. “If successful, we’ll apply for a Department of Defense grant,” Vyas said.
Unique facility
This summer, NanoViricides began moving into the 18,000-square-foot facility in Shelton, off Long Hill Cross Road. The firm is based in West Haven.
The Shelton building includes research and production labs that meet high purity standards, with various sets of locked doors. “Everything is kept very clean,” Diwan said.
Anil R. Diwan, president and chairman of NanoViricides Inc., left, shows U.S. Sen. Richard Blumenthal the facility.
It is the only nanomedicine clinical product manufacturing facility in Connecticut, said Diwan, who was born in India and is a bioscience researcher with a doctoral degree, an inventor, a patent-holder and an entrepreneur.
In addition to Ebola, NanoViricides is pursuing treatments for influenza, HIV, oral and genital herpes, dengue fever, and pink eye (conjunctivitis).
Potential for ‘thousands’ of employees
The company now has about 25 employees in Shelton, but plans to triple the workforce in the next year or two. Most of these employees would be highly educated scientists.
If the company receives approval for any of its products, it could quickly employ “thousands of people” and the Shelton facility might have up to 500 employees, Diwan said.
Equipment inside the NanoViricides lab area.
The Shelton facility is large enough that it could be used for larger-scale manufacturing. “Quantity production needed to curb the current [Ebola] outbreak can be performed readily in our new facility,” according to NanoViricides material.
A bioscience hub
Vyas envisions Connecticut becoming a major bioscience hub of nanomedicine, with much activity already taking place at Yale and in New Haven as well as through the University of Connecticut.
“We really think this will be something big for the state,” she said.
NanoViricides is a publicly traded company that’s listed on the New York Stock Exchange. “It’s established,” Blumenthal said.
Happy new year to all my NANO FRIENDS
FORZANANO.
Azna
NNVC will happen!
We have a lot going on now.
And they have cash.
FN
Yeah !
People are waiting for the big news!
The entire flu market for Flucide is $2 billion in sales if Flucide is the only new drug.
Word, ya'll.....WORD